Vor Biopharma, Inc. VOR 深 滬
已收盤 07-02 16:00:00 美东时间
20.59
+2.200
+11.96%
華盛通- 最 高22.22
- 今 開18.72
- 成交量 391.13万股
- 最 低 18.672
- 昨 收 18.39
- 總市值 11.16亿
- 52周最高 53.20
- 市盈率 靜 --
- 換手率 7.22%
- 52周最低 6.50
- 委 比 -85.23%
- 總股本 5418.59万
- 歷史最高 1272.40
- 量 比 1.34
- 振 幅 19.29%
- 歷史最低 2.622
- 每 手 1
- 風險率 12.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 航空环境周涨38%，获美国防部5亿美元反无人机大单；RKLB 80亿美元收购案引爆太空板块！卫讯公司周涨34%
ABVX暴涨近50%，核心在研药物取得积极进展；航空环境周涨38%，获美国防部5亿美元反无人机大单；RKLB 80亿美元收购案引爆太空板块！卫讯公司周涨34%>>
07-03 17:17
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Thursday. Shares of Rivian Automotive Inc (NASDAQ:RIVN) rose sharply on Thursday after the company released second-quarter production and delivery figures and raised full year delivery forecast. The company produced 12,61...
07-02 22:24
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio, a clinical-stage biotechnology company focused on autoimmune diseases, granted stock options for 71,200 shares and RSUs for 15,150 shares to 7 new employees on July 1, 2026. The options have a $18.39 exercise price, a 10-year term, and vest over four years, with 25% after 12 months and the rest monthly over 36 months. RSUs vest similarly, with 25% after 12 months and the rest quarterly. Both are under the 2023 Inducement Plan.
07-02 21:30
Vor Biopharma shareholders back directors and governance measures
The latest update is out from Vor Biopharma ( ($VOR) ). At its 2026 Annual Meet...
06-13 04:39
Vor Bio Announces Conditional China National Medicinal Products Administration Approval Of Telitacicept For The Treatment Of Adult Patients With IgAN
The conditional approval is supported by positive efficacy and safety data from RemeGen's completed Phase 2 trial (18C014) and Phase 3 TELIGAN trial (18C021 Part A) in IgAN. RemeGen independently developed telitacicept
06-08 20:33
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
Vor Biopharma, Inc. ($VOR) announced an update on their ongoing clinical study....
06-05 00:33
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio granted stock options for 61,050 shares and RSUs for 12,900 shares to 10 new employees on June 1, 2026, under the 2023 Inducement Plan. The options have a $14.57 exercise price, a 10-year term, and vest over four years, with 25% after 12 months and the rest monthly. RSUs vest similarly but quarterly. Both are subject to continued employment and the terms of the Inducement Plan.
06-01 21:00
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $18
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $15 to $18.
05-14 21:19
